Embryonal rhabdomyosarcoma with metastases confined to the lungs: Report from the CWS Study Group
Authors:
- Tobias M. DantonelloTDTobias M. Dantonello
- Gustaf LjungmanGLGustaf Ljungman
- on behalf of the CWS Study GroupOGon behalf of the CWS Study Group
- 8 November 2010
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 56 (5) , 725-732
Abstract
Background: Embryonal rhabdomyosarcoma [RME] is the most common pediatric soft tissue sarcoma. Whereas the prognosis of localized rhabdomyosarcoma has improved, it remains poor for metastatic disease.Methods: We analyzed RME‐patients with isolated pulmonary metastases [PRME] treated in four consecutive CWS‐trials. Treatment included multiagent chemotherapy and local treatment of the primary tumor. Therapy of lung metastases after induction chemotherapy depended on response and individual decisions.Results: Twenty‐nine patients 5 cm. In addition to conventional chemotherapy, seven patients received high‐dose treatment and eight patients oral metronomic chemotherapy. The lung metastases were in remission after induction chemotherapy in 22 individuals. 19 patients received no local treatment of metastases; 3 patients had pulmonary metastasectomy and lung radiation was administered to 9 individuals. In total, 24/29 patients achieved a complete remission [CR]. Actuarial 5‐year event‐free and overall survival for all patients was 37.9 ± 18% and 48.7 ± 18%, respectively; it was 45.8 ± 20% and 58.3 ± 20% for the 24 patients who achieved a CR. Local treatment of metastases had no impact on the failure pattern. Younger age, good response, achievement of CR and maintenance‐treatment were favorable prognostic factors in univariate analysis.Conclusions: Children with PRME have a fair prognosis. Local treatment of metastases did not improve outcome in our sample. Metronomic treatment may be an attractive option for PREM‐patients. [correction made here after initial online publication]. Pediatr Blood Cancer 2011;56:725–732.Keywords
Funding Information
- German Childhood Cancer Foundation, Bonn, Germany; German Cancer Aid, Bonn, Germany; Förderkreis Krebskranke Kinder Stuttgart, Germany
This publication has 31 references indexed in Scilit:
- Cooperative Trial CWS-91 for Localized Soft Tissue Sarcoma in Children, Adolescents, and Young AdultsJournal of Clinical Oncology, 2009
- Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative GroupsJournal of Clinical Oncology, 2008
- Incidence and time trends of soft tissue sarcomas in German children 1985–2004 – A report from the population-based German Childhood Cancer RegistryEuropean Journal of Cancer, 2008
- European Intergroup Studies (MMT4-89 and MMT4-91) on Childhood Metastatic Rhabdomyosarcoma: Final Results and Analysis of Prognostic FactorsJournal of Clinical Oncology, 2004
- Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcoma—A Report From the Intergroup Rhabdomyosarcoma Study IVJournal of Clinical Oncology, 2003
- Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic DiseaseJournal of Clinical Oncology, 2001
- Results of Treatment for Soft Tissue Sarcoma in Childhood and Adolescence: A Final Report of the German Cooperative Soft Tissue Sarcoma Study CWS-86Journal of Clinical Oncology, 1999
- Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84European Journal of Cancer, 1998
- The Third Intergroup Rhabdomyosarcoma Study.Journal of Clinical Oncology, 1995
- Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: A retrospective european multi‐center analysisMedical and Pediatric Oncology, 1992